UK region nears 100% LBC screening
This article was originally published in Clinica
Executive Summary
285,000 (75%) of the 380,000 screens performed annually in the UK's West Midlands region of the NHS use liquid-based cytology (LBC). So said Hologic this week, reporting that nine of the region's 13 screening programmes have now converted from traditional Pap smear screening to LBC ThinPrep Pap Test, developed by Cytyc. "Substantial parts" of another two regions have also converted. The 13 programmes operate through 11 laboratories. All UK women aged 25-64 years are routinely invited for screening once every three years up to the age of 50, and then every five years. Cytyc became a wholly-owned subsidiary of Hologic in October 2007, in a $6.2bn merger (see Clinica No 1279, p 15).
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.